FindMyKOL
Clinical trialNCT07415018RecruitingInterventional

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

SponsorM.D. Anderson Cancer CenterEnrollment40Leptomeningeal Disease
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Md Anderson Cancer Center

    Houston, Texas, United States

    Rami Eldaya, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GadavistVUEWAY
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Jun 2026
Primary completion
31 Jul 2027
Completion
31 Jul 2029
Last update posted
18 Jun 2026
Registered enrollment
40
Registry id
NCT07415018
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.